Biotricity Q1 FY27 net loss widens 42.8% to $959,468; revenue rises 10.4% to $4.28 million

• Biotricity posted a GAAP net loss of $959,468 for the quarter ended June 30, 2026, widening from the prior-year quarter.
• Revenue rose 10.4% to $4.28 million, driven by a 23.6% increase in recurring technology fee revenue to $4.2 million.
• Operating income fell 43.9% to $158,068 as selling, general and administrative expense climbed 26.2% to $2.7 million.
• Gross margin improved 2.1 percentage points to 82.6%; technology fees made up 97.4% of revenue.
• Non-GAAP adjusted EBITDA increased to $499,526; GAAP EBITDA eased to $90,409 on higher share-based compensation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biotricity Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-039209), on August 19, 2026, and is solely responsible for the information contained therein.